Celgene's head of inflammation and immunology Scott Smith told investors this week that Otezla, mongersen (also known as GED-0301) and ozanimod are all expected to become blockbusters by the end ...

aiming to mount a challenge to Amgen's $2.3 billion oral psoriasis therapy Otezla (apremilast). BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by ...

For example, a study of apremilast (Otezla) in palmoplantar pustulosis showed that up to 70% of patients had at least a 50% reduction in disease severity after 16 weeks. Overall, the magnitude of ...

Improvements in disease severity and quality of life measures among adults with psoriasis who are receiving apremilast was independent of genital psoriasis involvement. Apremilast improves disease ...

Reports of combination therapy in IMIDs often involve apremilast, a phosphodiesterase 4 inhibitor, but given that “we think of apremilast as a potent anti-inflammatory and not necessarily ...